Articles from Ferrer

The seventh edition of the International Meeting on Pulmonary Hypertension Clinical Treatment (IMPAHCT), organized by the pharmaceutical company Ferrer, gathered over 150 experts in pulmonology and cardiology from more than 30 countries in Barcelona this past weekend. The event reaffirmed the clinical community’s commitment to multidisciplinary and international collaboration to improve the treatment of pulmonary hypertension (PH), a serious condition affecting 1% of the population. PH is often accompanied by debilitating symptoms and an increased risk of mortality.

Spanish pharmaceutical company Ferrer has reaffirmed its status as a B Corp, an international certification awarded to companies that operate with a business model centered on positive impact and meet high social, environmental, and community standards. Ferrer has achieved a score of 136.4 points, making it the highest-rated pharmaceutical company in the world. Additionally, it now ranks as the third-highest scoring company across all sectors globally among those generating more than €500 million in annual revenue.

Ferrer has achieved Compliance Leader Verification™, the prestigious recognition granted by Ethisphere, which distinguishes the pharmaceutical company as a global leader in upholding ethical and responsible corporate practices in its business operations.

Ferrer, a B Corp-certified international pharmaceutical company, has announced the dosing of the first participant in the Phase II clinical trial, PROSPER. The study seeks to evaluate the safety and efficacy of the molecule FNP-223,1 a novel therapy intended to slow the progression of Progressive Supranuclear Palsy (PSP).1,2

The cardiovascular polypill developed by the Spanish National Centre for Cardiovascular Research (CNIC) and Ferrer has been included by the World Health Organization (WHO) in its List of Essential Medicines1.

The pharmaceutical company Ferrer, certified as a B Corp in 2022, has again shown that there is another way of doing business, with an ethical business approach that contributes to a better society. Over the past three years, Ferrer has allocated over 40% on average of its net profits to various social and environmental projects aimed at creating a fairer and more equitable society. As stated in the company’s Sustainability Report, in 2022, 47% of profits were reinvested, carrying out the company's commitment to making a positive impact in society.

The IMPAHCT (International Meeting on Pulmonary Hypertension Clinical Treatment) event, organized by the pharmaceutical company Ferrer, has brought together more than 150 pulmonologists and cardiologists from over 30 countries, consolidating the company’s commitment to the advancement of the research and treatment of pulmonary hypertension.

The international pharmaceutical company Ferrer has announced the extension of its phase III clinical trial ADORE (ALS trial with Daily ORal Edaravone), with FNP122 in amyotrophic lateral sclerosis (ALS). The ADOREXT study offers the possibility of receiving FNP-122 to all ADORE participants that complete the full study period. Patients who stopped treatment (for other than safety reasons) but completed the study period will be also invited to participate in ADOREXT. All participants will remain in active treatment.

Spanish pharmaceutical company Ferrer and Swiss clinical stage biotechnology company Asceneuron announce the signing of a licensing agreement in which Ferrer obtains the exclusive worldwide rights to develop and commercialize ASN90 in progressive supranuclear palsy (PSP), an orphan, tau-related disease with a high unmet medical need1.

The polypill developed by the CNIC and Ferrer, which includes three drugs (aspirin, an angiotensin-converting enzyme (ACE) inhibitor, and a statin), is effective at preventing secondary adverse cardiovascular events in people who have previously had a heart attack. The polypill reduces mortality from cardiovascular causes in this population by 33%.